A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Exclusion Criteria

• •Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases as determined by CT or MRI evaluation during screening and prior radiographic assessments
• •History of leptomeningeal disease
• •Prior chemotherapy or other systemic therapy for stage IIIB, IIIC, or IV disease
• •Active or history of autoimmune disease or immune deficiency
• •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
• •Active tuberculosis
• •Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
• •History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
• •Prior allogeneic stem cell or solid organ transplantation
• •Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
• •Current treatment with anti-viral therapy for HBV
• •Treatment with investigational therapy within 28 days prior to initiation of study treatment
• •Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
• •Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
• •Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment
• •History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
• •Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulations
• •Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab, 6 months after the final dose of bevacizumab
• •Prior history of hypertensive crisis or hypertensive encephalopathy
• •Significant vascular disease within 6 months prior to initiation of study treatment
• •History of Grade ≥ 2 hemoptysis within 1 month prior to enrollment
• •Evidence of bleeding diathesis or coagulopathy. Current or recent use of aspirin, clopidogrel or treatment with dipyramidole, ticlopidine, or cilostazol
• •Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes that has not been stable for \> 2 weeks prior to enrollment
• •History of stroke or transient ischemic attack within 6 months prior to enrollment
• •Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first dose of bevacizumab
• •History of abdominal or tracheosphageal fistula or gastrointestinal perforation within 6 months prior to enrollment
• •History of intra-abdominal inflammatory process within 6 months prior to initiation of study treatment, including but not limited to active peptic ulcer disease, diverticulitis,or colitis
• •Clinical signs of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding
• •Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
• •Proteinuria
• •Clear tumor infiltration into the thoracic great vessels is seen on imaging
• •Clear cavitation of pulmonary lesions is seen on imaging